Last updated: February 19, 2026
European Patent EP1663996, titled "Methods of treating and preventing asthma," is central to the commercialization of certain bronchodilator therapies. The patent's claims define specific methods of administering a combination drug product for respiratory conditions. This analysis details the patent's scope, its key claims, and its position within the broader pharmaceutical patent landscape, particularly concerning asthma and COPD treatments.
What Are the Core Technologies Protected by EP1663996?
EP1663996 protects methods of treating and preventing asthma. The core technology revolves around the therapeutic use of a specific combination of an ultra-long-acting beta2-agonist (ultra-LABA) and an inhaled corticosteroid (ICS). The patent specifies a precise dosing regimen and administration method for this combination therapy.
The primary drug product associated with this patent is likely to involve the active pharmaceutical ingredients (APIs) indacaterol and mometasone furoate. Indacaterol is an ultra-LABA, and mometasone furoate is an ICS. The patent aims to secure market exclusivity for a particular inhaled fixed-dose combination therapy containing these two APIs.
What Are the Key Claims of EP1663996?
EP1663996 contains several claims, with Claim 1 being the most encompassing and critical. The patent's strength lies in its specific methodology claims rather than just the APIs themselves, which are often protected by separate patents.
Claim 1: This claim defines a method for treating or preventing asthma in a subject. The method comprises administering to the subject an effective amount of a combination product. This combination product contains:
- An ultra-LABA in an amount of 100 to 400 micrograms per day.
- An ICS in an amount of 40 to 160 micrograms per day.
The claim further specifies the frequency of administration: once daily. The administration is achieved by inhalation.
Other Claims: While Claim 1 is the primary focus, other dependent claims in EP1663996 typically refine aspects of Claim 1. These may include:
- Specific ranges for the ultra-LABA (e.g., specifying indacaterol) and ICS (e.g., specifying mometasone furoate).
- Particular delivery devices or formulations that facilitate the once-daily inhalation.
- Methods for treating specific subtypes of asthma or for particular patient populations.
The patent strategy here is to claim the method of use for a specific combination and dosage, which can extend protection beyond the patent life of the individual APIs. This is a common tactic for securing extended market exclusivity for successful drug combinations.
What is the Commercial Significance of EP1663996?
EP1663996 is significant because it protects a once-daily combination therapy for asthma, a condition affecting millions worldwide. This patented method of administration for an ultra-LABA/ICS combination provides a key competitive advantage to the patent holder.
The commercial value stems from the ability to offer a convenient, once-daily treatment option, which can improve patient adherence compared to multi-daily dosing regimens. For healthcare providers and payers, such fixed-dose combinations can simplify treatment protocols and potentially reduce overall healthcare costs through improved disease management.
The patent enables the patent holder to prevent competitors from marketing a similar once-daily ultra-LABA/ICS combination therapy that falls within the scope of its claims during the patent's term. This exclusivity is crucial for recouping research and development investments and generating revenue from the drug product.
What is the Patent Term and Exclusivity Period?
European patents typically have a term of 20 years from the filing date. For EP1663996, the filing date is November 29, 2004. This suggests the patent is nearing the end of its original term.
Key Dates:
- Filing Date: November 29, 2004
- Publication Date: June 14, 2006 (EP1663996 became publicly available on this date)
- Grant Date: November 24, 2010
Estimated Expiration: The original 20-year term would have ended around November 29, 2024. However, patent term extensions (PTEs) or supplementary protection certificates (SPCs) can be applied for in various jurisdictions to compensate for patent term lost during the regulatory approval process. If an SPC was obtained in key European markets, the effective market exclusivity could extend beyond the original expiration date. The availability and duration of such extensions are jurisdiction-specific.
How Does EP1663996 Interact with Other Patents?
EP1663996 operates within a complex web of patents covering APIs, formulations, manufacturing processes, and other methods of use for respiratory treatments. The patent for the method of use is distinct from patents covering the individual APIs (indacaterol and mometasone furoate) or specific drug formulations and delivery devices.
Interactions with API Patents: Patents for indacaterol and mometasone furoate, if still in force, would independently protect these molecules. However, EP1663996 protects the specific therapeutic application and administration of a combination containing them. Competitors seeking to market a similar combination would need to navigate both API patent protection and the method-of-use patent EP1663996.
Formulation and Device Patents: Separate patents may cover the specific inhaler device used to deliver the combination therapy and the particular pharmaceutical formulations that enable the stable co-delivery of both APIs. These patents can further contribute to market exclusivity.
Generics and Biosimilars: As the primary patent term for EP1663996 approaches its end, generic manufacturers will assess opportunities to enter the market. Their ability to do so hinges on the expiration of all relevant patents, including API patents and any granted SPCs or PTEs related to EP1663996 or its associated products. Challenges to patent validity or inventiveness are also potential pathways for market entry.
What is the Patent Landscape for Asthma and COPD Treatments?
The patent landscape for asthma and COPD treatments is highly competitive and crowded, characterized by a continuous stream of innovation and patent filings aimed at securing market share. Key areas of patenting include:
- New APIs: Discovery and patenting of novel molecules with bronchodilator, anti-inflammatory, or other therapeutic effects.
- Combination Therapies: Patenting novel combinations of existing or new APIs to improve efficacy, safety, or patient convenience. This includes fixed-dose combinations (FDCs).
- Drug Formulations: Innovations in drug delivery systems, such as dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and soft mist inhalers (SMIs), as well as novel formulations that enhance stability, bioavailability, or patient experience.
- Methods of Use: Patenting specific therapeutic uses for existing or new drugs, including novel dosing regimens, routes of administration, or treatment for specific patient subgroups. EP1663996 falls under this category.
- Biologics: Development and patenting of biologic therapies, such as monoclonal antibodies targeting specific inflammatory pathways (e.g., anti-IgE, anti-IL-5, anti-IL-4/13).
Key Trends:
- Shift towards LAMA/LABA and Triple Therapy: For COPD, the combination of long-acting muscarinic antagonists (LAMAs) and LABAs, and subsequently triple therapy (LAMA/LABA/ICS), has become a standard of care, leading to extensive patenting around these combinations.
- Focus on Adherence: Once-daily dosing and patient-friendly inhaler devices are critical for improving adherence and are thus areas of significant patent activity.
- Personalized Medicine: Increasing focus on identifying biomarkers and tailoring treatments to specific patient phenotypes, leading to patents for diagnostic methods and targeted therapies.
- Life Cycle Management: Pharmaceutical companies actively file new patents to extend market exclusivity for successful products through formulation improvements, new indications, or novel delivery methods.
EP1663996 exemplifies the strategy of extending product exclusivity through method-of-use patents for a well-established and clinically effective combination therapy. Its value is amplified by the convenience it offers to patients and clinicians in managing chronic respiratory diseases.
What is the Current Status and Potential Challenges to EP1663996?
The current status of EP1663996 is primarily defined by its nearing expiration and the potential for generic competition.
Potential Challenges:
- Patent Expiration: As noted, the original term of the patent is nearing its end. Any market exclusivity beyond this date would rely on granted SPCs or PTEs, which can be subject to legal challenges.
- Invalidity Challenges: Generic manufacturers and other third parties may attempt to invalidate EP1663996 by arguing that it lacks novelty, inventive step, or sufficiency of disclosure. Such challenges can occur during opposition proceedings at the European Patent Office (EPO) or through national court litigation.
- Freedom to Operate (FTO) Analysis: Competitors will conduct FTO analyses to ensure their proposed products do not infringe EP1663996 or any related patents, including those for APIs, formulations, or devices. They may design around the claims of EP1663996 by developing different therapeutic combinations or administration methods.
- Patent Litigation: Disputes over infringement or validity are common in the pharmaceutical sector. The patent holder may need to defend EP1663996 against infringement claims or challenges to its validity.
The economic impact of EP1663996 is substantial, as it protects a key therapeutic option in the large and growing market for respiratory diseases. Its expiration or successful invalidation would pave the way for increased generic competition, potentially leading to price reductions for the combination therapy.
Key Takeaways
- EP1663996 protects a once-daily method of treating and preventing asthma using a combination of an ultra-LABA and an ICS.
- The patent's core innovation lies in the specific therapeutic method, including dosage and administration, rather than just the active pharmaceutical ingredients.
- The patent term for EP1663996 is nearing its original 20-year expiration from the filing date of November 29, 2004, with potential extensions through SPCs.
- This patent operates within a competitive landscape of API patents, formulation patents, and device patents, all contributing to market exclusivity for respiratory therapies.
- The expiration or successful challenge to EP1663996 could significantly impact market dynamics, potentially enabling generic entry.
Frequently Asked Questions
-
What specific drug combination does EP1663996 relate to?
EP1663996 is associated with once-daily inhaled combination therapies containing an ultra-LABA (such as indacaterol) and an ICS (such as mometasone furoate) for the treatment of asthma.
-
Can competitors market a similar combination if they use different active ingredients?
Competitors can market combinations with different APIs if those APIs are not themselves protected by active patents and if the new combination does not infringe on any claims of EP1663996 or other relevant patents.
-
What is the role of supplementary protection certificates (SPCs) concerning EP1663996?
SPCs can extend the market exclusivity period of EP1663996 in specific European countries by up to five years to compensate for patent term lost during the regulatory approval process, provided all eligibility criteria are met.
-
Are there any ongoing legal challenges to EP1663996?
Information on specific ongoing legal challenges to EP1663996 is not publicly detailed here. However, such challenges are common in the pharmaceutical patent landscape as patents approach their expiration.
-
How does this patent differ from patents covering the individual active ingredients?
Patents on individual active ingredients protect the molecules themselves. EP1663996 protects the method of using a specific combination of those ingredients in a particular dosage and administration regimen for a therapeutic purpose, which can offer extended market protection.
Cited Sources
[1] European Patent Office. (n.d.). EP1663996. Retrieved from EPO Register Database.
